KITE, which started trading from Jun 2014, has a mixed record of earnings surprises. Meanwhile, KTE-C19 is being evaluated in other cancer studies as well. KTE-C19 is expected to be launched in 2017. Kite plans to initiate a rolling submission of the BLA by the end of December this year with a targeted completion by the end of the first quarter 2017.
Kite pharma yahoo finance license#
In September, the company announced encouraging top-line results from the phase II part of ZUMA-1 study and expects to file a Biologic license application (BLA) in the DLBCL, TFL and PMBCL indications, based on this data. All these are types of aggressive non-Hodgkin’s lymphoma (NHL). KITE-C19, its lead pipeline candidate, is currently in the pivotal phase of a phase I-II study (ZUMA-1) in patients with refractory diffuse large B cell lymphoma (DLBCL) including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). With no approved products in its portfolio, investor focus will primarily be on the company’s cash burn and pipeline updates.
Immuno-oncology is a hot therapeutic area with huge commercial potential. The modified T-cells are designed to recognize and destroy cancer cells. Exposes stock, commodity, futures, currency (FX), mutual fund, and ETF prices, stock fundamental, summary data. Kite uses eACT to genetically modify T cells to express either CARs or TCRs. Fetch stock market data from Yahoo Finance. KITE is a development-stage company focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer.
0 kommentar(er)
